Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib with glucocorticoids for IgG4-related disease
ChiCTR2500105444Phase 4Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Glucocorticoid + ivarmacitinib with Glucocorticoid + placebo (2 arms). Primary endpoints: Recurrence rate, Remission rate and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on ChiCTR2500105444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105444.